Edwards Lifesciences (EW) EBIT (2009 - 2026)

Edwards Lifesciences' EBIT history runs 18 years deep, the most recent figure standing at $477.6 million for Q1 2026.

• In Q1 2026, EBIT rose 20.97% year-over-year to $477.6 million; the TTM figure through Mar 2026 stood at $1.3 billion (down 5.44% YoY), while the FY2025 annual figure was $1.3 billion, down 8.3% from the prior year.
• EBIT was $477.6 million for Q1 2026 at Edwards Lifesciences, up from $151.1 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $477.6 million in Q1 2026 to a low of $151.1 million in Q4 2025.
• Historically, EBIT has averaged $352.0 million across 5 years, with a median of $365.9 million in 2023.
• The sharpest annual moves came in 2023 and 2025: EBIT surged 75.42% in 2023, then sank 51.66% in 2025.
• A 5-year view of EBIT shows it stood at $197.7 million in 2022, then soared by 75.42% to $346.8 million in 2023, then declined by 9.86% to $312.6 million in 2024, then tumbled by 51.66% to $151.1 million in 2025, then jumped by 216.08% to $477.6 million in 2026.
• The last three EBIT figures came in at $477.6 million (Q1 2026), $151.1 million (Q4 2025), and $307.1 million (Q3 2025), per Business Quant data.